GSE102505 5 V 3 TUNICAMYCIN HUMAN UP (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE102505 5 V 3 TUNICAMYCIN HUMAN UP.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE102505 5 V 3 TUNICAMYCIN HUMAN UP.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE102505 5 V 3 TUNICAMYCIN HUMAN UP.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE102505 5 V 3 TUNICAMYCIN HUMAN UP.

Results found

Linked to

 

Label

Description

 

Gene

ZNF593 opposite strand

Gene

transmembrane p24 trafficking protein 7

Gene

transmembrane protein 79

Gene

apoptosis inhibitor 5

Gene

tubulin tyrosine ligase like 7

Gene

phosphate regulating endopeptidase X-linked

Gene

FCF1 rRNA-processing protein

Gene

zDHHC palmitoyltransferase 24

Gene

hexokinase domain containing 1

Gene

1-aminocyclopropane-1-carboxylate synthase homolog (inactive)

  • Gene

    ZNF593 opposite strand


  • Gene

    transmembrane p24 trafficking protein 7


  • Gene

    transmembrane protein 79


  • Gene

    apoptosis inhibitor 5


  • Gene

    tubulin tyrosine ligase like 7


  • Gene

    phosphate regulating endopeptidase X-linked


  • Gene

    FCF1 rRNA-processing protein


  • Gene

    zDHHC palmitoyltransferase 24


  • Gene

    hexokinase domain containing 1


  • Gene

    1-aminocyclopropane-1-carboxylate synthase homolog (inactive)

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.